: Hyperthermic therapy has been applied in many advanced malignancies, but tumor regression occurs only in thermo-sensitive cancers. To elucidate ways to overcome thermo-resistance and to improve the therapeutic efficiency of treating thermo-resistant cancers, we devised a novel application of cancer gene therapy in conjunction with hyperthermia. This strategy allows for selective cancer gene therapy under control of the heat-inducible HSP promoter. Heat-inducible activity of HSP promoter was examined in FM3A breast cancer cell line and MKN45 gastric cancer cell line using a luciferase assay reporter gene system. HSP promoter activity increased markedly following heat shock, and this increase depended on temperature and duration of treatment. Based on these results, we designed a suicide gene therapy using the Herpes simplex virus thymidine kinase gene ligated to the heat-inducible HSP promoter (HSP-tk). In in vitro cytotoxic assays HSP-tk transduced cells following heat treatment became 50,000 times more sensitive than either non-transduced cells or HSP-tk transduced cells without heat treatment to ganciclovir (GCV). Immunohistochemical analysis revealed that Fas-mediated apoptosis was involved in the synergistic killing effect of combination therapy. Next, we examined the efficacy of HSP-tk gene therapy in vivo, cancer cell lines implants in subcutaneous or intraperitoneal models of balb/c nude mice were targeted using the HVJ-anionic-liposome method. Significant inhibition of tumor growth was observed in HSP-tk transduced tumors following hyperthermia as more than half of treated-mice showed complete tumor eradication. Prolonged survival was also observed in HSP-tk transducted mice with hyperthermia.
Introduction
Hyperthermia is a promising treatment option for advanced cancer, as radiofrequency capacitative heating devices have been used successfully for localized heating of tumors without noxious effects on adjacent normal tissues ". However, highly malignant cancers are usually thermoresistant due to HSP70 production 2). More than 300 cancer gene therapy clinical trials have been carried out, but a efficient and selective gene therapy has not been developed yet. Thus, we reasoned that hyperthermia in combination with gene therapy, designed to target HSP70, might be useful in improving quality of life and prolonging survival times in cases of advanced cancers. In this review, we summarize a novel strategy of suicide gene therapy in conjunction with hyperthermia based on our studies of breast and gastric cancer cell lines and later describe a possible future application for human cancer gene therapy using a modified liposome vector system.
Approaches to cancer gene therapy
One of the first strategies proposed for the use of recombinant DNA constructs in cancer patients that employed systemic injection of a non-toxic drug precursor; tumor cells were transduced with a specific enzyme gene whose product would convert a precursor into a toxic metabolite in the cells. In the first protocol to be approved using this strategy, brain tumors were transfected with a retroviral vector expressing the Herpes simplex virus thymidine kinase (HSV-tk) gene. Gancyclovir (GCV) delivering systemically was metabolized to cytotoxic gancyclovir triphosphates by cells expressing HSV-tk3' . Studies in a rat glioma model showed that marked tumor regression occurred even if only a small fraction of tumor cells were transfected with the HSV-tk gene. This cytotoxic effect on untransfected cells has been termed the "bystander effect" 4).
While extensive testings of retroviral vector based-therapies have not revealed major signs of toxicity, it has failed to demonstrate significant effectiveness in clinical trials of cancer patients. Whereas adenoviral vectors used for localized treatment have had limited success. However the severe side effects includings hepatotoxicity and demylination can result from adenoviral-mediating HSV-tk gene therapy when using a constitutively active CMV promoter5)6). Thus, a potential advantage of using a regulatable promoter-based gene therapy is that it might restrinct suicide gene expression to tumor cells.
Tumor targeting by gene therapy under the control of promoter
Tumor targeting under the control of promoter is classified as shown in Table I . Previous studies in cancer gene therapy have investigated various cell type-specific promoters including mucin-1 , c-erbB-2 Cells were incubated with various concentrations of GCV for 5 days, followed by cell survival quantitation as previously described '3) Data are concentration of GCV yielding 50% growth inhibition (IC50) and therapeutic index comparing untreated cells with heat-treated cells. Induction of HSP70 promoter activity by heat shock.
To estimate the levels of transcriptional activation of the HSP promoter, we performed luciferase assays using the human HSP promoter ligated upstream of the luciferase gene. Relative luciferase activity in FM3A cells increased by approximately 100 to 400 fold between 3 to 12 h after heat shock (Fig. 3A) . In contrast, there was no significant increase in promoter activity in tsFT101 cells.
To confirm that increased HSP promoter activity resulted in production of heat shock factors, we performed gel mobility shift assays'''. These assays showed significant induction of heat shock factors in FM3A, but not in tsFT101.
We next exzamined HSP promoter activation by heat treatment in gastric cancer cell lines, MKN45 (Fig.   3B ), NUGC3, and colon cancer cell lines, DLD-1, LoVo, 100-2000 fold activation was observed in all cell lines.
In vitro gene therapy FM3A cells were retrovirally transfected with the expression unit containing HSV-tk DNA ligated to the HSP promoter (HSP-tk). Non-transfected and transfected cells were subjected to heat shock and treatment with GCV in various combinations. GCV (0-100 ,a g/ml) had no killing effect in HSP-tk-transfected FM3A (FM3A-HSPtk) in the absence of heat. Further GCV had no effect in non-transfected FM3A cells with or without heat treatment. In contrast, cells expressing HSP-tk and treated with heat shock were about 50,000 times more sensitive to GCV than cells that were not treated by heat shock (Table II) .
To determine the mechanism of enhanced killing by heat shock, we examined to detect the presence of 
Mechanisms of bystander effect
In addition to molecular targeting by appropriate promoter selection, enhancement of the bystander effect is also important for suicide gene therapy. This is because it is impossible for the in vivo gene delivery system to transfer the gene into all cells in relatively large tumors 25). Several successful bystander effects have been reported to activate tumor immunity by cytotoxic T-cells using syngenic animal models 26) ") . However, patients with advanced cancers are immuno-compromised hosts. Therefore, we examined the potential bystander effect of gene therapy with the GCV/HSV-tk system in combined with hyperthermia in a nude mouse model lacking T-cell immunity. Tumors from each treatment group (control, heat shock, gene therapy and combination therapy) were analyzed by hematoxylin-eosin staining. The number of apoptotic cells exhibiting shrunken nuclei and apoptotic bodies increased in the combination group, whereas there was no increase in apoptotic cells in control, hyperthermia or gene therapy group (Fig. 5) . We confirmed these binding by analyzing TUNEL stained sections ") .
Additionally, leukocyte infiltration was not observed in any groups. These results suggest that the synergistic tumor cell killing effect of combination therapy depends upon apoptosis, but not on NK cell or T-cell mediated tumor immunity.
To test which apoptotic signal pathway is involved in enhancement of bystander effect , we analyzed expression are sensitive to hyperthermia, and those expressing HSP70 may be thermotolerant but have a robust response to gene therapy (Fig. 6 ). Thus, a very wide therapeutic range may be anticipated not only in vitro, but also in vivo, further suggesting that this combination regimen is a potentially suitable treatment modality for advanced cancer.
